Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin
Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review
DOI
- https://doi.org/10.1111/ane.13322
Final published version
- Anne-Kathrine Ryltoft ,
- Ali Al-Zuhairy, Rigshospitalet ,
- Soren H. Sindrup, Odense University Hospital ,
- Henning Andersen
- Lars K. Markvardsen
Background: Subcutaneous immunoglobulin (SCIG) is effective treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Quality of life (QoL) increases following switch from intravenous administration to SCIG, but its correlation with clinical functioning is sparsely studied.
Aims of the study: The aim of this study is to evaluate the correlation between QoL and clinical functioning in CIDP patients treated with SCIG.
Methods: Danish patients with CIDP with a disease duration
Results: Of 92 eligible patients, 44 were included. QoL on the visual analogue scale (VAS) was 65% (range: 15-90) of the level of healthy controls (P = .03) and correlated to impaired gait function by 40-MWT and 6-SST. QoL correlated to RODS and ODSS, whereas there was no correlation with the MRC score.
Conclusions: In SCIG treated CIDP patients QoL is reduced and correlates to gait performance and disability.
| Original language | English |
|---|---|
| Book series | Acta Neurologica Scandinavica. Supplementum |
| Volume | 142 |
| Issue | 6 |
| Pages (from-to) | 637-640 |
| Number of pages | 4 |
| ISSN | 0001-6314 |
| DOIs | |
| Publication status | Published - Dec 2020 |
- chronic inflammatory demyelinating polyneuropathy, quality of life, subcutaneous immunoglobulin, CIDP, MMN, VALUES
Research areas
See relations at Aarhus University Citationformats
ID: 195425232